<DOC>
	<DOCNO>NCT00110123</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fotemustine , work different way stop growth tumor cell , either kill cell stop divide . Giving drug different way may kill tumor cell . It yet know whether give fotemustine intravenous infusion effective give hepatic arterial infusion treat liver metastasis . PURPOSE : This randomized phase III trial study intravenous infusion fotemustine see well work compare hepatic arterial infusion fotemustine treat patient unresectable liver metastasis eye melanoma .</brief_summary>
	<brief_title>Intravenous Hepatic Arterial Infusion Fotemustine Treating Patients With Unresectable Liver Metastases From Eye Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient surgically incurable unresectable liver metastasis secondary uveal melanoma treat fotemustine administer intravenous infusion v intra-arterial hepatic perfusion . Secondary - Compare progression-free survival patient treated drug . - Compare response rate patient treat drug . - Compare duration objective response patient treated drug . - Compare pattern progression patient treat drug . - Compare treatment-related toxic effect catheter-related complication patient treated drug . OUTLINE : This open-label , randomize , multicenter study . Patients stratify accord participate center , lactic dehydrogenase level ( normal v abnormal ) , WHO performance status ( 0 vs 1 v 2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive fotemustine IV 1 hour day 1 , 8 , 15 ( induction course ) . Beginning day 50 , patient receive maintenance course fotemustine IV 1 hour every 21 day absence disease progression unacceptable toxicity . - Arm II : Patients receive fotemustine 4-hour intra-arterial ( IA ) hepatic perfusion day 1 , 8 , 15 , 22 ( induction course ) . Beginning day 57 , patient receive maintenance course fotemustine 4-hour IA hepatic perfusion every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 9 week survival . PROJECTED ACCRUAL : A total 262 patient ( 131 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Fotemustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm liver metastasis secondary uveal melanoma Surgically incurable unresectable disease No detectable extrahepatic metastasis PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Hepatic Bilirubin &lt; 1.5 time upper limit normal ( ULN ) ALT AST &lt; 5 time ULN Alkaline phosphatase &lt; 5 time ULN Gammaglutamyltransferase &lt; 5 time ULN Lactic dehydrogenase &lt; 5 time ULN Renal BUN &lt; 1.5 time ULN Creatinine ≤ 1.5 time ULN Cardiovascular No uncontrolled angina pectoris No myocardial infarction within past 6 month No uncontrolled high blood pressure No evolutive intracranial hypertension No severe cardiac disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active gastroduodenal ulcer No diabetes No active uncontrolled infection No psychological , familial , sociological , geographical condition would preclude study compliance followup No uncontrolled severe medical condition No malignancy within past 5 year except surgically cure carcinoma situ cervix basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunologic biologic therapy Chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy metastatic disease No concurrent radiotherapy Surgery Recovered prior major surgery Other No prior antineoplastic drug metastatic disease More 4 week since prior investigational drug No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>metastatic intraocular melanoma</keyword>
</DOC>